{
    "clinical_study": {
        "@rank": "131137", 
        "arm_group": [
            {
                "arm_group_label": "Neonate dosing cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Neonate dexmedetomidine dosing cohort 1"
            }, 
            {
                "arm_group_label": "Neonate dosing cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Neonate dexmedetomidine dosing cohort 2"
            }, 
            {
                "arm_group_label": "Neonate dosing cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "Neonate dexmedetomidine dosing cohort 3"
            }, 
            {
                "arm_group_label": "Neonate dosing cohort 4", 
                "arm_group_type": "Experimental", 
                "description": "Neonate dexmedetomidine dosing cohort 4"
            }, 
            {
                "arm_group_label": "Neonate dosing cohort 5", 
                "arm_group_type": "Experimental", 
                "description": "Neonate dexmedetomidine dosing cohort 5"
            }, 
            {
                "arm_group_label": "Infant dosing cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Infant dexmedetomidine dosing cohort 1"
            }, 
            {
                "arm_group_label": "Infant dosing cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Infant dexmedetomidine dosing cohort 2"
            }, 
            {
                "arm_group_label": "Infant dosing cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "Infant dexmedetomidine dosing cohort 3"
            }, 
            {
                "arm_group_label": "Infant dosing cohort 4", 
                "arm_group_type": "Experimental", 
                "description": "Infant dexmedetomidine dosing cohort 4"
            }, 
            {
                "arm_group_label": "Infant dosing cohort 5", 
                "arm_group_type": "Experimental", 
                "description": "Infant dexmedetomidine dosing cohort 5"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this Phase I study is to determine the safety of a drug called\n      dexmedetomidine (DEX) as part of a balanced general anesthetic and sedative strategy for\n      neonates and infants undergoing corrective cardiac surgery that requires the use of\n      cardiopulmonary bypass for congenital cardiac problems. This study will also design and\n      validate a dosing schema for the use of DEX as described above."
        }, 
        "brief_title": "A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Transposition of the Great Arteries", 
            "Tetralogy of Fallot", 
            "Ventricular Septal Defect"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Heart Septal Defects", 
                "Heart Septal Defects, Ventricular", 
                "Tetralogy of Fallot", 
                "Transposition of Great Vessels"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, age 0 to 90 days.\n\n          -  Diagnosis of: D-transposition of the great arteries (with or without ventricular\n             septal defect), or tetralogy of Fallot, or ventricular septal defect (with or without\n             associated atrial septal defect and/or patent ductus arteriosus)\n\n          -  Scheduled for complete corrective two-ventricle surgical repair with cardiopulmonary\n             bypass.\n\n        Exclusion Criteria:\n\n          -  Less than 37 completed weeks' gestational age at birth.\n\n          -  Known or suspected hepatic dysfunction; AST and ALT >3X upper limit of normal at the\n             time of screening within 72 hours of operation.\n\n          -  Known or suspected renal dysfunction; serum creatinine > 0.8 mg/dL within 72 hours of\n             operation.\n\n          -  Preoperative administration of DEX or clonidine within 72 hours of operation.\n\n          -  Major congenital anomaly(ies) outside the cardiovascular system.\n\n          -  Preoperative central nervous system injury resulting in clinical signs and symptoms:\n             coma, seizures, hemiparesis.\n\n          -  Planned period of deep hypothermic circulatory arrest.\n\n          -  History of second or third degree heart block.\n\n          -  Sinus or junctional bradycardia below 80 BPM sustained for greater than 15 minutes\n             within 72 hours of operation.\n\n          -  Junctional rhythm sustained for greater than 15 minutes within 72 hours of operation.\n\n          -  Hypotension defined as mean arterial blood pressure below 35 mm Hg for 0-21 day old\n             neonatal patients, and below 40 mm Hg for 22- 90 day old infant patients sustained\n             for greater than 15 minutes within 72 hours of operation.\n\n          -  History of cardiac arrest or ECMO cannulation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Days", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "106", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01915277", 
            "org_study_id": "PHN-DEX"
        }, 
        "intervention": {
            "arm_group_label": [
                "Neonate dosing cohort 1", 
                "Neonate dosing cohort 2", 
                "Neonate dosing cohort 3", 
                "Neonate dosing cohort 4", 
                "Neonate dosing cohort 5", 
                "Infant dosing cohort 1", 
                "Infant dosing cohort 2", 
                "Infant dosing cohort 3", 
                "Infant dosing cohort 4", 
                "Infant dosing cohort 5"
            ], 
            "intervention_name": "Dexmedetomidine", 
            "intervention_type": "Drug", 
            "other_name": "Precedex, dexmedetomidine HCl"
        }, 
        "intervention_browse": {
            "mesh_term": "Dexmedetomidine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Pediatric corrective cardiac surgery", 
        "lastchanged_date": "April 4, 2014", 
        "location": {
            "contact": {
                "email": "dbandrop@texaschildrens.org", 
                "last_name": "Dean B Andropoulos, MD", 
                "phone": "832-826-5822"
            }, 
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "Texas Children's Hospital"
            }, 
            "investigator": {
                "last_name": "Dean B Andropoulos, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "10", 
        "official_title": "A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The occurrence of any of the following that is possibly, probably, or definitely related to DEX administration:\nBradycardia\nHeart block\nJunctional rhythm\nHypotension\nExcessive sedation\nCardiac arrest or ECMO cannulation\nSerious Adverse Event (SAE)\nBoth the DEX dose, and DEX exposure will be assessed for associations with the primary outcome.", 
            "measure": "The occurrence of a safety event that is possibly, probably or definitely related to DEX administration", 
            "safety_issue": "Yes", 
            "time_frame": "Within 4 hours after DEX adminstration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01915277"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Plasma concentrations of dex obtained intraoperatively and up to 36 hours post-operatively will be used to create drug dosing models.  These models will then be evaluated to determine how effective they are at achieving targeted plasma concentration levels.", 
            "measure": "Plasma concentration of DEX", 
            "safety_issue": "No", 
            "time_frame": "Intraoperatively and up to 36 hours post-operatively"
        }, 
        "source": "New England Research Institutes", 
        "sponsors": {
            "collaborator": {
                "agency": "National Heart, Lung, and Blood Institute (NHLBI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "New England Research Institutes", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}